CLINICAL_TRIALS ClinicalTrials.gov record update

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma (Phase I/IIa) the BELI(E)VE-Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05853965
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:40.850054+00:00
Published At: 2025-03-30T00:00:00+00:00
Record Updated At: 2025-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma", "Multiple Myeloma in Relapse"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-30"
protocolSection.identificationModule.nctId: "NCT05853965"
protocolSection.identificationModule.officialTitle: "Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma (Phase I/IIa) the BELI(E)VE-Trial"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.